An analysis of the mutations that developed after treatment demonstrated a tumor subclone harboring mutations of TOP1 (which encodes topoisomerase-1, the target of the SG payload), along with a distinct subclone harboring a mutation of TACSTD2 (which encodes TROP2, the antigen target of SG). This evidence concerns the gene TACSTD2 and neoplasm.